Twist Bioscience Corporation and LenioBio GmbH have entered a collaborative agreement to integrate their respective DNA and protein expression technologies [1].

This partnership aims to streamline the pipeline for AI-driven drug discovery. By combining synthetic DNA with cell-free protein production, the companies intend to reduce the time and cost associated with identifying viable therapeutic candidates.

LenioBio GmbH is a TechBio company that commercializes the ALiCE® cell-free protein expression platform [2]. Under the terms of the agreement, this platform will be integrated with the DNA technology provided by Twist Bioscience [2]. The synergy between these two systems allows researchers to move from a digital genetic sequence to a physical protein more efficiently.

Traditional drug discovery often relies on living cells to produce proteins, a process that can be slow and unpredictable. The ALiCE® platform bypasses these cellular requirements, allowing for a more controlled environment to test AI-generated protein designs [2]. Twist Bioscience provides the high-quality synthetic DNA required to feed these systems, creating a closed loop between digital design and biological validation.

"LenioBio GmbH, a TechBio company commercializing its ALiCE® cell-free protein expression platform, today announced a collaborative agreement with Twist Bioscience Corporation," LenioBio said [2].

The agreement was announced on May 8, 2026 [2]. It positions both companies to capture a larger share of the AI-enabled biotechnology market as pharmaceutical firms seek to automate the early stages of drug development. The integration is designed to enable a more rapid iterative cycle of design, build, and test for novel proteins [2].

“The collaboration integrates cell-free protein expression with DNA technology”

This collaboration represents a shift toward 'TechBio,' where the boundary between computer science and biology blurs. By removing the need for living cells in the initial protein expression phase, the companies are attempting to remove a primary bottleneck in the drug discovery process. If successful, this integration could allow AI to not only predict how a drug should work but to physically produce and test those predictions at a speed previously impossible in traditional laboratories.